$ONC
BeiGene, Ltd. Stock $onc

$onc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000165130824000014 Filed on February 26, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$751.7M	$4.548B	$2.459B
YoY Change	67.85%	68.6%	73.65%
Cost Of Revenue	$938.2M	$819.4M	$2.710B
YoY Change	1047.06%	63.26%	846.0%
Gross Profit	$626.7M	$3.729B	$2.079B
YoY Change	71.23%	69.82%	84.06%
Gross Profit Margin	83.38%	81.98%	84.55%
Selling, General & Admin	$427.4M	$2.958B	$1.505B
YoY Change	30.12%	24.94%	17.74%
% of Gross Profit	68.2%	79.32%	72.37%
Research & Development	$460.6M	$3.636B	$1.779B
YoY Change	12.74%	15.99%	8.42%
% of Gross Profit	73.5%	97.51%	85.56%
Depreciation & Amortization	$25.29M		$87.68M
YoY Change	26.4%		32.28%
% of Gross Profit	4.04%		4.22%
Operating Expenses	$888.1M	$6.589B	$3.283B
YoY Change	20.48%	19.39%	12.5%
Operating Profit	-$261.3M	-$2.860B	-$1.208B
YoY Change	-29.6%	-13.93%	-32.52%
Interest Expense	$71.41M	$236.1M	-$59.34M
YoY Change	-30.4%	-4.25%	-95.76%
% of Operating Profit
Other Income/Expense, Net	$1.762M	-$902.0K	$307.9M
YoY Change	-90.37%	-26.0%	-237.54%
Pretax Income	-$243.4M	-$2.625B	-$825.8M
YoY Change	-27.75%	-14.71%	-57.89%
Income Tax	$7.724M	$212.9M	$55.87M
% Of Pretax Income
Net Earnings	-$251.2M	-$2.838B	-$881.7M
YoY Change	-27.92%	-11.55%	-56.0%
Net Earnings / Revenue	-33.41%	-62.39%	-35.86%
Basic Earnings Per Share	-$0.19		-$0.65
Diluted Earnings Per Share	-$0.19	-$2.11	-$0.65
COMMON SHARES
Basic Shares Outstanding	1.360B shares	1.359B shares	1.357B shares
Diluted Shares Outstanding	1.356B shares		1.357B shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.13B	$22.55B	$22.55B
YoY Change	-17.22%	-15.82%	-28.28%
Cash & Equivalents	$2.793B	$3.172B
Short-Term Investments	$5.720B	$7.515B	$7.515B
Other Short-Term Assets	$1.205B	$1.083B	$1.083B
YoY Change	-68.89%	-82.36%	-19.18%
Inventory	$447.3M	$416.1M	$2.951B
Prepaid Expenses
Receivables	$435.3M	$358.0M	$2.538B
Other Receivables	$346.5M	$685.6M	$685.6M
Total Short-Term Assets	$3.908B	$4.203B	$29.81B
YoY Change	-16.93%	-19.27%	-17.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.418B	$1.324B	$9.318B
YoY Change	53.23%	56.53%	52.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$41.12M	$25.98M	$635.2M
YoY Change	27.04%	-6.24%	-0.41%
Other Assets	$199.0M	$125.4M	$304.3M
YoY Change	14.8%	-26.44%	-42.47%
Total Long-Term Assets	$1.760B	$1.602B	$11.31B
YoY Change	40.52%	36.65%	40.51%
TOTAL ASSETS
Total Short-Term Assets	$3.908B	$4.203B	$29.81B
Total Long-Term Assets	$1.760B	$1.602B	$11.31B
Total Assets	$5.668B	$5.805B	$41.12B
YoY Change	-4.85%	-9.0%	-7.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$356.6M	$315.1M	$3.680B
YoY Change	47.74%	6.9%	48.23%
Accrued Expenses	$569.4M	$693.7M	$2.568B
YoY Change	36.25%	48.44%	52.53%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$5.689B	$4.684B	$4.684B
YoY Change	210.23%	112.63%	112.63%
Long-Term Debt Due	5.971B cnies	4.886B cnies	$358.8M
YoY Change	208.51%	115.34%	35.98%
Total Short-Term Liabilities	$1.882B	$1.810B	$12.83B
YoY Change	49.99%	23.26%	24.56%
LONG-TERM LIABILITIES
Long-Term Debt	1.437B cnies	1.403B cnies	$1.562B
YoY Change	1.43%	-2.76%	-7.21%
Other Long-Term Liabilities	$48.90M	$50.51M	$1.567B
YoY Change	7.19%	9.58%	-15.78%
Total Long-Term Liabilities	$425.6M	$457.8M	$3.129B
YoY Change	-21.89%	-13.19%	-11.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.882B	$1.810B	$12.83B
Total Long-Term Liabilities	$425.6M	$457.8M	$3.129B
Total Liabilities	$2.307B	$2.268B	$16.02B
YoY Change	28.22%	13.63%	15.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.213B	-$7.962B
YoY Change	10.56%	12.45%
Common Stock	$136.0K	$135.0K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.360B	$3.537B	$25.10B
YoY Change
Total Liabilities & Shareholders Equity	$5.668B	$5.805B	$41.12B
YoY Change	-4.85%	-9.0%	-7.02%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$251.2M	-$2.838B	-$881.7M
YoY Change	-27.92%	-11.55%	-56.0%
Depreciation, Depletion And Amortization	$25.29M		$87.68M
YoY Change	26.4%		32.28%
Cash From Operating Activities	-$308.6M	-$2.392B	-$1.157B
YoY Change	-45.27%	78.37%	-22.66%
INVESTING ACTIVITIES
Capital Expenditures	$156.6M	$1.009B	$561.9M
YoY Change	24.68%	17.14%	72.66%
Acquisitions
YoY Change
Other Investing Activities	$19.43M	-$1.697B	$4.223B
YoY Change	110.1%	-55.51%
Cash From Investing Activities	-$209.8M	-$2.706B	$60.00M
YoY Change	-187.04%	-42.12%	-94.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net	$3.579M		$13.69M
YoY Change	145.64%
Cash From Financing Activities	$162.3M	2.308B	$416.5M
YoY Change	-916.86%	-358.94%	-2295.34%
NET CHANGE
Cash From Operating Activities	-$308.6M	-2.392B	-$1.157B
Cash From Investing Activities	-$209.8M	-2.706B	$60.00M
Cash From Financing Activities	$162.3M	2.308B	$416.5M
Net Change In Cash	-$378.5M	-2.790B	-$689.1M
YoY Change	14.27%	-59.61%	35.68%
FREE CASH FLOW
Cash From Operating Activities	-$308.6M	-$2.392B	-$1.157B
Capital Expenditures	$156.6M	$1.009B	$561.9M
Free Cash Flow	-$465.2M	-$3.401B	-$1.719B
YoY Change	-32.52%	54.42%	-5.64%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001651308
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37686
CY2023	dei	Entity Registrant Name EntityRegistrantName	BEIGENE, LTD.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1209416
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	c/o Mourant Governance Services (Cayman) Limited
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	94 Solaris Avenue, Camana Bay
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Grand Cayman
CY2023	dei	Entity Address Country EntityAddressCountry	KY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	KY1-1108
CY2023	dei	City Area Code CityAreaCode	345
CY2023	dei	Local Phone Number LocalPhoneNumber	949 4123
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	10500000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1359513224	shares
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2458779000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1415921000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1176283000	usd
CY2023	us-gaap	Gross Profit GrossProfit	2078859000	usd
CY2022	us-gaap	Gross Profit GrossProfit	1129446000	usd
CY2021	us-gaap	Gross Profit GrossProfit	1011377000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1778594000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1640508000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1459239000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1504501000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1277852000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	990123000	usd
CY2023	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	3500000	usd
CY2022	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	751000	usd
CY2021	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	750000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	3286595000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	2919111000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	2450112000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1207736000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1789665000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1438735000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	74009000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	52480000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-15757000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	307891000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-223852000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15904000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-825836000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1961037000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1438588000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55872000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42778000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19228000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1357034547	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1357034547	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1340729572	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1340729572	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1206210049	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1206210049	shares
CY2023	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-8.45
CY2023	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-8.45
CY2022	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-19.43
CY2022	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-19.43
CY2021	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-15.71
CY2021	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-15.71
CY2023	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	104387273	shares
CY2023	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	104387273	shares
CY2022	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	103133044	shares
CY2022	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	103133044	shares
CY2021	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	92785388	shares
CY2021	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	92785388	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3171800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3869564000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11473000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	196000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	2600000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	665251000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	358027000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	173168000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	416122000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	282346000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	243392000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	216553000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4203414000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5207078000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1324154000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	845946000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	95207000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	109960000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57138000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40616000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	125362000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	175690000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1601861000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1172212000	usd
CY2023Q4	us-gaap	Assets Assets	5805275000	usd
CY2022Q4	us-gaap	Assets Assets	6379290000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	315111000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	294781000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	693731000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	467352000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	213861000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	22951000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	25189000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21950000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24041000	usd
CY2023Q4	bgne	Research And Development Cost Share Liability Current Portion ResearchAndDevelopmentCostShareLiabilityCurrentPortion	68004000	usd
CY2022Q4	bgne	Research And Development Cost Share Liability Current Portion ResearchAndDevelopmentCostShareLiabilityCurrentPortion	114335000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	688366000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	328969000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1810113000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1468528000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	197618000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	209148000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	300000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	42026000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22251000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34517000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	16494000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	15996000	usd
CY2023Q4	bgne	Research And Development Cost Share Liability Noncurrent Portion ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion	170662000	usd
CY2022Q4	bgne	Research And Development Cost Share Liability Noncurrent Portion ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion	179625000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	50510000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	46095000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	457835000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	527407000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2267948000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1995935000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	9500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	9500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1359513224	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1359513224	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1356140180	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1356140180	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	135000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	135000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11598688000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11540979000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-99446000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-77417000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7962050000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7080342000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3537327000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4383355000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5805275000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6379290000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-881708000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2003815000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25464000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-90421000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	13714000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	5611000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-365000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-1865000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	9046000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5311000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4571000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-903737000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2099182000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1446808000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-881708000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2003815000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1457816000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	87675000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	66278000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	46457000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	367618000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	303162000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	240712000	usd
CY2023	bgne	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	46800000	usd
CY2022	bgne	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	68665000	usd
CY2021	bgne	Acquired In Process Research And Development AcquiredInProcessResearchAndDevelopment	83500000	usd
CY2023	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-55294000	usd
CY2022	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-96402000	usd
CY2021	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-112486000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-16221000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-21996000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	7632000	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	689000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	2059000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	3377000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	362917000	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-5998000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	9047000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	23510000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	188306000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-304112000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	423019000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	140948000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56689000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	153333000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-12120000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3282000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	107128000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	21484000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4352000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	20008000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	180111000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	45627000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	140044000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-255587000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-151816000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	407703000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	587000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1209000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2620000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1157453000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1496619000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1298723000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	561896000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	325434000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	262942000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	2075000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	1485000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	2147881000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	673240000	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	1563618000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3146891000	usd
CY2023	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	15000000	usd
CY2022	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	143665000	usd
CY2021	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	8500000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	19365000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	43409000	usd
CY2023	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	14900000	usd
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	15911000	usd
CY2021	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	43500000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	60004000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1077123000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	640659000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	3392616000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000000	usd
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	22502000	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	37372000	usd
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	16838000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	13690000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	661530000	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	313774000	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	406449000	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	309576000	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	417081000	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	321754000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	55712000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	46964000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	92762000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	416478000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18971000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3636911000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-8082000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-69383000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14035000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-689053000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-507850000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2992882000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3875037000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4382887000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1390005000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3185984000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3875037000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4382887000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3171800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3869564000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4375678000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11473000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	196000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	328000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2711000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5277000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6881000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	56003000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	29500000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	15695000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	19753000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	25169000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	29967000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	91804000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	95346000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	53197000	usd
CY2023	bgne	Acquired In Process Research And Development But Not Yet Paid AcquiredInProcessResearchAndDevelopmentButNotYetPaid	31800000	usd
CY2022	bgne	Acquired In Process Research And Development But Not Yet Paid AcquiredInProcessResearchAndDevelopmentButNotYetPaid	0	usd
CY2021	bgne	Acquired In Process Research And Development But Not Yet Paid AcquiredInProcessResearchAndDevelopmentButNotYetPaid	75000000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2500000000	usd
CY2023	bgne	Revenue From Contract With Customer Excluding Assessed Tax Period Increase Decrease RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease	1000000000	usd
CY2022	bgne	Net Income Loss Including Portion Attributable To Noncontrolling Interest Period Increase Decrease NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease	1100000000	usd
CY2023Q4	bgne	Number Of Approved Medicines NumberOfApprovedMedicines	3	medicine
CY2023Q4	bgne	Number Of Approved Medicines Company Has Rights To NumberOfApprovedMedicinesCompanyHasRightsTo	14	medicine
CY2023Q4	bgne	Number Of Internal Clinical Teams NumberOfInternalClinicalTeams	3000	team
CY2023Q4	bgne	Clinical Trials Conducted ClinicalTrialsConducted	130	trial
CY2023Q4	bgne	Number Of Patients NumberOfPatients	22000	patient
CY2023Q4	bgne	Number Of Regions NumberOfRegions	45	region
CY2023Q4	dei	Entity Number Of Employees EntityNumberOfEmployees	10000	employee
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and the standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.</span></div>
CY2023	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	7529000	usd
CY2021	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2022	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of cash and credit risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to credit risk consist of cash and cash equivalents, short-term investments, and accounts receivable.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, $3,171,800 and $3,869,564 were deposited with various major reputable financial institutions located in the PRC and international financial institutions outside of the PRC, respectively. The deposits placed with financial institutions are not protected by statutory or commercial insurance. In the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions. As of December 31, 2023 and 2022, the Company had short-term investments amounting to $2,600 and $665,251, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2023 and 2022, the Company’s short-term investments were comprised of U.S. treasury securities. The Company believes that U.S. treasury securities are of high credit quality and continually monitors the credit worthiness of these institutions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and 2022, the Company had accounts receivable, net of $358,027 and $173,168, respectively. Accounts receivable, net represent amounts arising from product sales. The Company monitors economic conditions to identify facts or circumstances that may indicate receivables are at risk of collection.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer concentration risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, sales to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s four largest product distributors, ASD Specialty Healthcare, McKesson, Sinopharm, and Shanghai Pharmaceutical, represented approximately 16.0%, 14.2%, 12.4% and 11.4% of product revenue, respectively, and collectively, represented approximately 53.2% of trade accounts receivable as of December 31, 2023. For the year ended December 31, 2023, the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s collaboration revenue consisted primarily of revenue recognized under its out-licensing collaboration agreements with Novartis.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, sales to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s four largest product distributors, Sinopharm, Shanghai Pharmaceutical, ASD Specialty Healthcare and China Resources represented approximately 18.1%, 15.5%, 14.2% and 12.1% of product revenue, respectively, and collectively, represented approximately 57.0% of trade accounts receivable as of December 31, 2022. For the year ended December 31, 2022, the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s collaboration revenue consisted entirely of revenue recognized under its out-licensing collaboration agreements with Novartis. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, sales to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s three largest product distributors, Sinopharm, China Resources, and Shanghai Pharmaceutical represented approximately 26.0%, 19.9% and 16.7% of product revenue, respectively, and collectively, represented approximately 23.4% of trade accounts receivable as of December 31, 2021. For the year ended December 31, 2021, the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s collaboration revenue consisted entirely of revenue recognized under its out-licensing collaboration agreements with Novartis. Receivables from Novartis represented approximately 66.4% of trade accounts receivable as of December 31, 2021, primarily due to the invoicing of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$300,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upfront fee related to the Ociperlimab option, collaboration and license agreement.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3171800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3869564000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	2600000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	665251000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	358027000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	173168000	usd
CY2022Q1	bgne	Number Of Products Initiated Marketing And Promotion NumberOfProductsInitiatedMarketingAndPromotion	5	product
CY2022Q1	bgne	Number Of Products Initiated Marketing And Promotion NumberOfProductsInitiatedMarketingAndPromotion	5	product
CY2023Q4	bgne	Number Of Ongoing Trials NumberOfOngoingTrials	2	trial
CY2023	bgne	Reimbursement Expense ReimbursementExpense	50871000	usd
CY2022	bgne	Reimbursement Expense ReimbursementExpense	50183000	usd
CY2021	bgne	Reimbursement Expense ReimbursementExpense	42836000	usd
CY2023	bgne	Upfront And Milestone Payments UpfrontAndMilestonePayments	71165000	usd
CY2022	bgne	Upfront And Milestone Payments UpfrontAndMilestonePayments	74165000	usd
CY2021	bgne	Upfront And Milestone Payments UpfrontAndMilestonePayments	141894000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	19365000	usd
CY2021Q2	bgne	Number Of Designated Therapeutic Targets NumberOfDesignatedTherapeuticTargets	4	target
CY2021Q2	bgne	Number Of Targets NumberOfTargets	2	target
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	11473000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	196000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2711000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	14184000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	5473000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	2565000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	35000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	2600000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	674262000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9011000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	665251000	usd
CY2021	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2022	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	55860000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	57054000	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount	6448000	usd
CY2022	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	5065000	usd
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	0	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	148772000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	88957000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	39098000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	20886000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	228252000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	172503000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	416122000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	282346000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	25978000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	25938000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	22536000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	6101000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	6834000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4892000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1683000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1299000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1823000	usd
CY2023	us-gaap	Lease Cost LeaseCost	33762000	usd
CY2022	us-gaap	Lease Cost LeaseCost	34071000	usd
CY2021	us-gaap	Lease Cost LeaseCost	29251000	usd
CY2023	us-gaap	Depreciation Depreciation	80436000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	95207000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	109960000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21950000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24041000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22251000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34517000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	44201000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	58558000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	23499000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14148000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5740000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3155000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1682000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	932000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	49156000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4955000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	44201000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	27985000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	28064000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	19962000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11854000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22278000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	37454000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0722
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0576
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	832751000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	723789000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	249212000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	171470000	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	740615000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	293627000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1324154000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	845946000	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	740615000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	293627000	usd
CY2022	us-gaap	Depreciation Depreciation	62302000	usd
CY2021	us-gaap	Depreciation Depreciation	44742000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	73261000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16123000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57138000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	49551000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8935000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40616000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7239000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3976000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1715000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	5000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4999000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4776000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4776000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	32587000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57138000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-825836000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1961037000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1438588000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-411818000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	25170000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4844000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-9000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	24956000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27905000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	15252000	usd
CY2023	bgne	Current Other Income Tax Expense Benefit CurrentOtherIncomeTaxExpenseBenefit	5059000	usd
CY2022	bgne	Current Other Income Tax Expense Benefit CurrentOtherIncomeTaxExpenseBenefit	6547000	usd
CY2021	bgne	Current Other Income Tax Expense Benefit CurrentOtherIncomeTaxExpenseBenefit	805000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	55185000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	39296000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	16048000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-35000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	687000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3480000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4919000	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	2000	usd
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-1704000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	687000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3482000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3180000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55872000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42778000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19228000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-825836000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1961037000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1438588000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-173426000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-302103000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	141902000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	209692000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	128330000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	19134000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	29223000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	361000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	32581000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	33872000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-27411000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3464000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1375000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3187000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	845811000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	229550000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	254768000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	704928000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	0	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	0	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	64343000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	42844000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	31530000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	37395000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	6272000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Fdii Amount EffectiveIncomeTaxRateReconciliationFdiiAmount	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	55872000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42778000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19228000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.068
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.022
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.013
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	106708000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	97896000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	84766000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	996588000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	862214000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	625114000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	26687000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	19700000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14982000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	68117000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	86000000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	82060000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	704928000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	687600000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	798563000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	937069000	usd
CY2023Q4	bgne	Deferred Tax Assets Property Lease Liability Obligation DeferredTaxAssetsPropertyLeaseLiabilityObligation	7893000	usd
CY2022Q4	bgne	Deferred Tax Assets Property Lease Liability Obligation DeferredTaxAssetsPropertyLeaseLiabilityObligation	10348000	usd
CY2021Q4	bgne	Deferred Tax Assets Property Lease Liability Obligation DeferredTaxAssetsPropertyLeaseLiabilityObligation	11571000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	164190000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	63156000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2023Q4	bgne	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset	7735000	usd
CY2022Q4	bgne	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset	10098000	usd
CY2021Q4	bgne	Deferred Tax Assets Right Of Use Asset DeferredTaxAssetsRightOfUseAsset	11322000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2754976000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1927779000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1744240000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2771470000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1943775000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1758409000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	16494000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	15996000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	14169000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1943775000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1758409000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1200547000	usd
CY2023	bgne	Deferred Tax Asset Valuation Allowance Changes Included In Earnings DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings	845811000	usd
CY2022	bgne	Deferred Tax Asset Valuation Allowance Changes Included In Earnings DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings	229550000	usd
CY2021	bgne	Deferred Tax Asset Valuation Allowance Changes Included In Earnings DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings	254768000	usd
CY2023	bgne	Deferred Tax Asset Valuation Allowance Gain Loss Included In Other Comprehensive Income Loss DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss	0	usd
CY2022	bgne	Deferred Tax Asset Valuation Allowance Gain Loss Included In Other Comprehensive Income Loss DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss	0	usd
CY2021	bgne	Deferred Tax Asset Valuation Allowance Gain Loss Included In Other Comprehensive Income Loss DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss	-263632000	usd
CY2023	bgne	Deferred Tax Asset Valuation Allowance Currency Translation And Other DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther	-18116000	usd
CY2022	bgne	Deferred Tax Asset Valuation Allowance Currency Translation And Other DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther	-44184000	usd
CY2021	bgne	Deferred Tax Asset Valuation Allowance Currency Translation And Other DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther	39462000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2771470000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1943775000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1758409000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5945753000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5077247000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11555000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9925000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7123000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2709000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1630000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2802000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14264000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11555000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9925000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2023Q4	bgne	Tax Benefit From Foreign Tax Status TaxBenefitFromForeignTaxStatus	3092000	usd
CY2023Q4	bgne	Tax Benefit From Foreign Tax Status Per Share TaxBenefitFromForeignTaxStatusPerShare	0.01
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	2969000	usd
CY2023Q4	bgne	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	60476000	usd
CY2022Q4	bgne	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	71488000	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	37320000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	20478000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	36124000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	22777000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1735000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	3039000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	8872000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3664000	usd
CY2023Q4	bgne	Prepaid Manufacturing Costs PrepaidManufacturingCosts	42066000	usd
CY2022Q4	bgne	Prepaid Manufacturing Costs PrepaidManufacturingCosts	58950000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	56799000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	36157000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	243392000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	216553000	usd
CY2023Q4	bgne	Prepayment Of Long Term Asset PrepaymentOfLongTermAsset	4144000	usd
CY2022Q4	bgne	Prepayment Of Long Term Asset PrepaymentOfLongTermAsset	22025000	usd
CY2023Q4	bgne	Prepaid Supply Cost PrepaidSupplyCost	18122000	usd
CY2022Q4	bgne	Prepaid Supply Cost PrepaidSupplyCost	48642000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	2546000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	804000	usd
CY2023Q4	bgne	Rental Deposits And Other RentalDepositsAndOther	8195000	usd
CY2022Q4	bgne	Rental Deposits And Other RentalDepositsAndOther	7054000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2711000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	5277000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	89644000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	91779000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	0	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	109000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	125362000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	175690000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	217803000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	184775000	usd
CY2023Q4	bgne	Accrued Liabilities External Research And Development AccruedLiabilitiesExternalResearchAndDevelopment	162969000	usd
CY2022Q4	bgne	Accrued Liabilities External Research And Development AccruedLiabilitiesExternalResearchAndDevelopment	139168000	usd
CY2023Q4	bgne	Accrued Expenses Commercial Activities AccruedExpensesCommercialActivities	87572000	usd
CY2022Q4	bgne	Accrued Expenses Commercial Activities AccruedExpensesCommercialActivities	51806000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	30083000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	18815000	usd
CY2023Q4	bgne	Accrued Sales Rebates And Returns Current AccruedSalesRebatesAndReturnsCurrent	139936000	usd
CY2022Q4	bgne	Accrued Sales Rebates And Returns Current AccruedSalesRebatesAndReturnsCurrent	41817000	usd
CY2023Q4	bgne	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	55368000	usd
CY2022Q4	bgne	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	30971000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	693731000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	467352000	usd
CY2023Q4	bgne	Government Grants Or Incentives Received And Deferred Noncurrent GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent	34204000	usd
CY2022Q4	bgne	Government Grants Or Incentives Received And Deferred Noncurrent GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent	38176000	usd
CY2023Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	14995000	usd
CY2022Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	7760000	usd
CY2023Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	1127000	usd
CY2022Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	0	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	184000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	159000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	50510000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	46095000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	688366000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4885838000	cny
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	328969000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2268905000	cny
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	197618000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1402643000	cny
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	209148000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1442500000	cny
CY2023Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	688366000	usd
CY2023Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	35565000	usd
CY2023Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	46279000	usd
CY2023Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	46279000	usd
CY2023Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	25146000	usd
CY2023Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	44349000	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	885984000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	20800000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	21699000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	29263000	usd
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	16571000	usd
CY2022	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	2594000	usd
CY2021	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1054000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	72204888	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.08
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	12516816	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.34
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.40
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5898217	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	52258000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2296634	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-881708000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2003815000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1457816000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1357034547	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1357034547	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1340729572	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1340729572	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1206210049	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1206210049	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	84991715	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.27
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6244524	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.46
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.40
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	17233853	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	367110000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1797498	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	13.27
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.46
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	76526853	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.85
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9817925	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.37
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.14
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6974331	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.54
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	92051000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1225334	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.60
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	78145113	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.06
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M2D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	465231000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	59221091	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.93
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M28D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	452750000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	75306510	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.81
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y11M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	463359000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	61121000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	62548000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	53571000	usd
CY2022	bgne	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Exercise Multiple Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum	2.8
CY2021	bgne	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Exercise Multiple Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum	2.8
CY2022	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-96178000	usd
CY2022	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-811000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-22840000	usd
CY2023	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-811000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	367588000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	303162000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	240712000	usd
CY2023Q4	bgne	Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage	0.10
CY2023Q4	bgne	Restricted Net Assets Required Statutory Reserve As Percentage Of Registered Capital RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital	0.50
CY2023Q4	bgne	Restricted Net Assets Appropriated To Statutory Reserves RestrictedNetAssetsAppropriatedToStatutoryReserves	0	usd
CY2022Q4	bgne	Restricted Net Assets Appropriated To Statutory Reserves RestrictedNetAssetsAppropriatedToStatutoryReserves	0	usd
CY2021Q4	bgne	Restricted Net Assets Appropriated To Statutory Reserves RestrictedNetAssetsAppropriatedToStatutoryReserves	0	usd
CY2023Q4	bgne	Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage	0.10
CY2023	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	169212000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2458779000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1415921000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1176283000	usd

Files In Submission

Name	View Source	Status
bgne-20231231_cal.xml	Edgar Link	unprocessable
0001651308-24-000014-index-headers.html	Edgar Link	pending
0001651308-24-000014-index.html	Edgar Link	pending
0001651308-24-000014.txt	Edgar Link	pending
0001651308-24-000014-xbrl.zip	Edgar Link	pending
bgne-20231231.htm	Edgar Link	pending
bgne-20231231.xsd	Edgar Link	pending
bgne-20231231_g1.jpg	Edgar Link	pending
bgne-20231231_g10.jpg	Edgar Link	pending
bgne-20231231_g11.jpg	Edgar Link	pending
bgne-20231231_g12.jpg	Edgar Link	pending
bgne-20231231_g13.jpg	Edgar Link	pending
bgne-20231231_g14.jpg	Edgar Link	pending
bgne-20231231_g15.jpg	Edgar Link	pending
bgne-20231231_g16.jpg	Edgar Link	pending
bgne-20231231_g17.jpg	Edgar Link	pending
bgne-20231231_g18.jpg	Edgar Link	pending
bgne-20231231_g19.jpg	Edgar Link	pending
bgne-20231231_g2.jpg	Edgar Link	pending
bgne-20231231_g20.jpg	Edgar Link	pending
bgne-20231231_g21.jpg	Edgar Link	pending
bgne-20231231_g22.jpg	Edgar Link	pending
bgne-20231231_g23.jpg	Edgar Link	pending
bgne-20231231_g24.jpg	Edgar Link	pending
bgne-20231231_g25.jpg	Edgar Link	pending
bgne-20231231_g26.jpg	Edgar Link	pending
bgne-20231231_g27.jpg	Edgar Link	pending
bgne-20231231_g28.jpg	Edgar Link	pending
bgne-20231231_g3.jpg	Edgar Link	pending
bgne-20231231_g4.jpg	Edgar Link	pending
bgne-20231231_g5.jpg	Edgar Link	pending
bgne-20231231_g6.jpg	Edgar Link	pending
bgne-20231231_g7.jpg	Edgar Link	pending
bgne-20231231_g8.jpg	Edgar Link	pending
bgne-20231231_g9.jpg	Edgar Link	pending
exhibit1016-consultingagre.htm	Edgar Link	pending
exhibit1021bmssettlementag.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
bgne-20231231_def.xml	Edgar Link	unprocessable
bgne-20231231_lab.xml	Edgar Link	unprocessable
bgne-20231231_pre.xml	Edgar Link	unprocessable
bgne-20231231_htm.xml	Edgar Link	completed
exhibit191-insidertradingp.htm	Edgar Link	pending
exhibit192-specialtradingp.htm	Edgar Link	pending
exhibit21-2023q4beigeneltd.htm	Edgar Link	pending
exhibit231-2023q4.htm	Edgar Link	pending
exhibit232-2023q4.htm	Edgar Link	pending
exhibit311-2023q4.htm	Edgar Link	pending
exhibit312-2023q4.htm	Edgar Link	pending
exhibit321-2023q4.htm	Edgar Link	pending
exhibit46-descriptionofsec.htm	Edgar Link	pending
exhibit97-compensationreco.htm	Edgar Link	pending
exhibit991-disclosureforei.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONC
BeiGene, Ltd. Stock $onc

2024 Q1 Form 10-K Financial Statement

#000165130824000014 Filed on February 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONC BeiGene, Ltd. Stock $onc

2024 Q1 Form 10-K Financial Statement

#000165130824000014 Filed on February 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONC
BeiGene, Ltd. Stock $onc